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Background: Right ventricular (RV) failure due to increased pressure load causes signiﬁcant morbidity and
mortality in patients with congenital heart diseases and pulmonary arterial hypertension. It is unknownwhether
renin–angiotensin–aldosterone-system (RAAS) inhibition (the cornerstone of left ventricular failure treatment)
is effective in RV failure. We investigated the effects of combination treatment of aldosterone-blocker
eplerenone + angiotensin II receptor blocker losartan (Ep/Lo) on RV remodeling and function in a model of
RV failure due to increased pressure load.
Methods and results: Rats (n = 48) were randomized for pulmonary artery banding (PAB) or sham surgery and
for losartan (20 mg/kg/d) + eplerenone (100 mg/kg/d) treatment (Ep/Lo) or vehicle (VEH). RV function was
assessed by echocardiography and pressure–volume analysis at 5 and 11 weeks, or at the occurrence of clinical
RV failure symptoms necessitating termination.
PAB resulted in RV failure in all rats, as deﬁned by reduced cardiac output, RV stroke volume, increased RV end
diastolic pressure and liver congestion as well as RV ﬁbrosis, hypertrophy and reduced capillary density. Clinical
RV failure necessitated termination in 5/12 PAB–VEH rats. Angiotensin II type 1-receptor expression in the RV
was reduced in PAB rats indicating local RAAS activation. Treatment of PAB rats with Ep/Lo signiﬁcantly lowered
arterial pressures, but hadno signiﬁcant effect on RV function, remodeling or survival compared to PAB–VEH rats.
Conclusions: RAAS inhibition does not beneﬁcially affect experimental RV failure due to chronic pressure load. This
is of high clinical relevance, because it indicates that theRV response toRAAS inhibitionmight fundamentally differ
from that of the LV.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Right ventricular (RV) failure due to pressure load is a primary
risk factor for early mortality and morbidity in patients with congenital
heart diseases and the main cause of death in pulmonary arterial
hypertension [1–4]. Despite the recognized clinical importance of
preserving RV function, the mechanisms of RV dysfunction and failure
are yet unknown and as a consequence there are no clinically established
treatments for RV failure [5]. This is in sharp contrast with left ventricular
(LV) failure [6,7] and it is tempting to extrapolate proven treatment stra-
tegies for LV failure to the RV. This is, however, associatedwith a number
of potential hazards. The RV differs functionally and morphologically
from the LV [8,9] and the RV derives embryologically from a distinct set
of precursor cells [10], implicating that the RV cardiomyocytes responset Diseases, Pediatric Cardiology,
rsity Medical Center Groningen,
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td. All rights reserved.to stress might be fundamentally different [5,11,12]. Furthermore,
the RV is coupled to the pulmonary circulation, physiologically a low
pressure, high compliance circulation with different properties than the
systemic circulation, which might affect the RV response to commonly
used LV drugs [13]. However, the implications of these differences
between RV and LV for the treatment of RV failure remain largely
speculative and the effects on RV failure of proven treatment strategies
for LV failure are insufﬁciently studied [14].
One of the cornerstones in the treatment of LV failure is inhibition
of an over-activated renin–angiotensin–aldosterone-system (RAAS)
with angiotensin II converting enzyme-inhibitors (ACEi) or angiotensin
II receptor blocker (ARB) combined with an aldosterone receptor
blocker [6,7]. RAAS inhibition has been shown to improve LV function
and attenuate adverse remodeling (ﬁbrosis, hypertrophy, and ventricular
dilatation) in (pre)clinical studies of LV failure [15–19].
Clinical studies suggest that RAAS over-activation might also play
a role in RV adaptation to various forms of abnormal loading and RV
failure [20]. Such data suggest patients with a systemic RV to be prime
candidates for RAAS inhibiting treatment, as their RV is chronically pres-
sure loaded and prone to failure. However, trials of ACEi [21,22] or ARBs
[23–25] in this patient group, reported negative results. Most of these
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spective set-up [26].
Preclinical data could provide a proof-of-principle that RAAS inhibi-
tion is beneﬁcial for the chronically pressure loaded RV. Unfortunately,
data regarding the in vivo functional effects of RAAS inhibition on the
pressure loaded RV are lacking. Therefore, we tested both functional
and histological effects of long-term combined pharmacological inhibi-
tion of the angiotensin II receptor (type 1) and the aldosterone receptor
by losartan/eplerenone treatment in a model of pressure load induced
RV failure.
We hypothesized that this clinically applicable treatment would
attenuate remodeling and, as a consequence, sustain RV function and
prevent RV failure.
2. Materials and methods
2.1. Animal model and study design
Animal care and experiments were conducted according to the Dutch Animal Exper-
imental Act and conform to the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The
Animal Experiments Committee of theUniversity of Groningen, theNetherlands approved
the experimental protocol.
Wistar rats (n = 48;male; 160–180 g; Charles River, theNetherlands)were random-
ized to pulmonary artery banding (PAB) or sham surgery. PAB (n = 33)was performed to
induce RV pressure overload, as described previously [27], except that for this study we
used a tighter PAB size (19G; 1.1 mm instead of 1.3 mm). Three rats died during PAB
surgery (1 severe bleeding, 1 acute RVF, 1 trachea perforation). The remaining 30 animals
with PAB were randomly assigned to a group of 15 rats to receive vehicle or a group of 15
rats to receive eplerenone and losartan. Inadvertently, the last three animals assigned to
the vehicle-group received eplo-treatment from the start, resulting in a vehicle-treated
group (PAB, n = 12) and an eplerenone and losartan treated group (PAB-eplo, n = 18).
After randomization, pairs were made between both groups, so that each PAB rat had a
paired PAB-eplo rat, which made it possible to terminate the rats pair-wise in case of
clinical deterioration. Sham operated animals (n = 15) underwent the PAB procedure
without the actual banding of the pulmonary artery and served as control (CON), and
were randomized into vehicle-treated (CON, n = 7) and treated (CON-eplo, n = 8)
groups.
2.2. Termination
Rats were terminated when clinical RVF (see Deﬁnition of clinical RV failure below)
developed. Along with the failing rat, the paired rat was terminated at the same time
point. At 11 weeks after surgery, all remaining rats (all CON(-eplo) rats and the remaining
PAB(-eplo) rats) were terminated.
One rat (in the PAB-eplo group) developed an abdominal tumor within two weeks
after PAB and was terminated. This animal had severe unilateral hydroureteronephrosis
and was excluded from further analysis.
2.3. Deﬁnition of clinical RV failure
Rats were examined daily for clinical signs of RV failure according to a previously
described checklist examining for appearance, activity, bodyweight changes, peripheral
circulation, cyanosis, dyspnea/tachypnea and edema/effusions. Clinical RV failure was
deﬁned as the presence of at least: inactivity, rufﬂed fur, severe dyspnea and palpable
ascites. The decision whether RV failure was present or not was made by 2 experienced
observers who were blinded to the experimental group of the rats [27].
2.4. RAAS-inhibiting treatment
Treatment was given from the moment of surgery onward and consisted of
the combination of angiotensin II receptor (type 1) blocker losartan (20 mg/kg BW/d)
[28,29] via the drinking water and mineralo-corticoid receptor blocker eplerenone
(100 mg/kg BW/d) [15,30] mixed in conventional rat chow, which have been previously
shown to be effective dosages in models of LV disease [15,28–30]. The untreated groups
received conventional rat chow and regular drinking water throughout the experiment.
2.5. Echocardiography
Transthoracal echocardiography was performed under general anesthesia
(isoﬂurane/air mixture: 5% induction, 2–3% maintenance) in all animals at 5 weeks
after surgery and at termination as described previously [27] using a Vivid Dimen-
sion 7 system and 10S-transducer (GE Healthcare, Waukesha, WI, USA). We used
apical 3- and 4-chamber views and parasternal short and long axis views to measure
RV and right atrial dimensions, tricuspid insufﬁciency, tricuspid annular plane
systolic excursion (TAPSE), and continuous wave Doppler for the gradient across
the PAB. Cardiac output was calculated as (aorta diameter)2 × 3.14 × velocity timeintegral × heart rate, using systolic aorta diameter and pulsed wave Doppler
measurements of aorta ﬂow. Measurements from 6 to 12 consecutive beats were
used to average out beat-to-beat variation.
2.6. Heart catheterization
Hemodynamic assessment of the RV was performed by pressure–volume analysis,
obtained at termination byRVcatheterization according to a previously describedprotocol
[27].
Brieﬂy, the rats were anesthetized (isoﬂurane/air mixture, 5% induction; 2–3% main-
tenance), intubated and ventilated. Following bilateral thoracotomy and pericardiotomy a
pressure-conductance catheter (SPR-869, Millar Instruments Inc., Houston, TX, USA) was
introduced into the RV apically and positioned in the RV outﬂow tract. RV pressures and
conductance were recorded using a MPVS 400 processor at a sample rate of 1.000 Hz
with Chart 5 (Millar Instruments Inc., Houston, TX, USA). Analyses were performed ofﬂine
using custom-made software (CircLab 2012, P. Steendijk). Stroke volume (in mL)
measured by echocardiography was used to calibrate stroke volume (in arbitrary units)
derived from the conductance signal. End systolic and end diastolic elastance was deter-
mined using the single-beat method [31]. Following the RV measurements, the catheter
was introduced in the aorta and the LV via the right carotid artery to measure systemic
pressures.
2.7. Organ weights, hypertrophy and ﬁbrosis
After heart catheterization, the rats were terminated by excising the heart–lung block
from the thorax. The heart, lungs and liver were dissected. RV, interventricular septum, LV
and both atria were separated and weighed. The liver lobe and lung lobe were weighed,
dried overnight at 65 °C and weighed again to determine wet weight/dry weight ratio.
Midventricular RV sections were ﬁxated (formalin) and stained to assess cardiomyocyte
cross-sectional area (wheat germ agglutinin), ﬁbrosis (Masson Trichrome) and capillary
density (lectin) as described previously [27,32].
2.8. Gene expression of RAAS and remodeling
To assess activation of the local RAAS, mRNA expression of the angiotensin II
receptors types 1 and 2 (AT1R and AT2R) were measured. To study the underlying
mechanisms of putative effects of Ep/Lo treatment the expression of key markers of
the fetal gene program (myosin heavy chain isoforms, natriuretic pro-peptides
types A and B) were measured, as well as genes involved in myocardial remodeling:
hypertrophy (ACTA, RCAN1), ﬁbrosis (TGFβ-1, OPN-1, Col1A2, and Col3A1) and oxi-
dative stress (HO-1, NOX-4). RV (free wall) tissue was snap-frozen in liquid nitrogen.
Total RNA was extracted using TRIzol reagent (Invitrogen Corporation, Carlsbad, CA,
USA); high quality was conﬁrmed (RQI 9.3) using Experion (Bio-Rad, Veenendaal,
the Netherlands), before conversion to cDNA by QuantiTect Reverse Transcription
(Qiagen, Venlo, the Netherlands). Gene expression was measured with Absolute
QPCR SYBR Green ROX mix (Abgene, Epsom, UK) in the presence of 7.5 ng cDNA
and 200 nM forward and reverse primers. qRT-PCR was carried out on the Bio-Rad
CFX384 (Bio-Rad, Veenendaal, the Netherlands) using a standard protocol of
maximally 35 cycles. Primer sequences are available upon request. mRNA levels are
expressed in relative units based on a standard curve obtained by a calibrator cDNA
mixture. All mRNA levels were corrected for 36B4 reference gene expression.
2.9. Statistical analysis
Quantitative data are expressed as mean ± standard error of the mean (SEM). CON
versus PAB differences were evaluated using Students t-test or Mann–Whitney U test as
appropriate. Treatment effects were tested by ANOVA with Bonferroni post-hoc testing
for multiple comparisons or Fisher's Exact Test as appropriate. Group sizes were 7
(CON); 8 (CON-eplo); 12 (PAB); 17 (PAB-eplo), unless speciﬁed otherwise. P b 0.05 was
considered signiﬁcant (PASW Statistics 18 for Windows, SPSS, Chicago, Illinois).
3. Results
3.1. Model characterization: pulmonary artery banding induces RV failure
in vehicle-treated rats
In vehicle-treated rats, pulmonary artery banding resulted in severe
pressure overload which induced (sub)clinical RV failure, characterized
by reduced cardiac index (Fig. 1A) and stroke volume (Fig. 1B), reduced
TAPSE (Fig. 1C), RV dilatation (Fig. 1D), tricuspid insufﬁciency (Fig. 1E),
right atrial enlargement (Fig. 1F), increased RV end diastolic pressure
(Fig. 1G) and liver congestion (Fig. 1H). Five of the 12 untreated rats de-
veloped overt clinical RVF within 11 weeks after PAB surgery, which
necessitated termination. Local RAAS was activated in the RV, indicated
by downregulation of AT1-receptor mRNA (Fig. 2). AT2-receptor mRNA
expression was not detectable at themaximum of 35 PCR cycles (Fig. 2).
Fig. 1. Model characterization: Pulmonary artery banding induces RV failure in vehicle-treated rats. A Cardiac index B RV stroke volume C tricuspid annular plane systolic excursion
(TAPSE) D RV end diastolic diameter (RVEDD) E percentage of rats with tricuspid insufﬁciency (TI) F right atrial diameter (RA) G RV end diastolic pressure (EDP) H liver wet weight:
dry weight ratio. All parameters measured by echocardiography, except EDP, whichwasmeasured by catheterization. Mean ± SEM. * indicates p b 0.05 between groups. CON= control,
PAB = pulmonary artery banding, both vehicle-treated.
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eling, including threefold increment of myocardial ﬁbrosis (Fig. 3A),
RV hypertrophy (expressed as RV weight/tibia length (Fig. 3B) or
cardiomyocyte cross-sectional area (Fig. 3C)), reduced capillary density
(Fig. 3B–D) and upregulation of hypertrophy related genes and the fetal
gene program (Table 2).3.2. Eplerenone/losartan treatment effects
Ep/Lo signiﬁcantly reduced left ventricular peak pressure and
aortic systolic and diastolic blood pressure in PAB (Fig. 4A–C). However,
Ep/Lo treatment did not have any signiﬁcant effect on RV hemodynam-
ics (Tables 1, S1), representative pressure–volume loops in Fig. 5A–C.
Contractility (end systolic elastance), active relaxation (tau) and passive
diastolic properties (end diastolic elastance, end diastolic pressure)
were unaffected by Ep/Lo (Table 1). Neither did Ep/Lo prevent dilation
of the RV and RA, tricuspid insufﬁciency or liver congestion (Table 1).
In line with this lack of hemodynamic beneﬁt, Ep/Lo treatment did not
delay (Fig. 5D) or prevent development of RV failure (5/17 vs. 5/12,
PAB vs. PAB-eplo, p = 0.494).
Myocardial ﬁbrosis and RV hypertrophywere not prevented by Ep/Lo
treatment (Fig. 3A–C). Ep/Lo also did not affect capillary density (Fig. 3D).
In line with this, expression of genes of the fetal gene program and genes
related to hypertrophy, ﬁbrosis and oxidative stress were unaffected by
Ep/Lo treatment (Table 2).
All parameters in CON and CON-eplo were equal (p = ns, data not
shown).Fig. 2. mRNA expression of angiotensin II receptor type 1 (AT1R) and 2 (AT2R). AT1R
(left panel) was downregulated in PAB. AT2R (right panel) was not detectable (nd) at
the 35th PCR cycle. Mean ± SEM. * indicates p b 0.05 between groups. CON = control,
PAB = pulmonary artery banding.4. Discussion
In this study we assessed the effects of proven LV failure treatment,
the combination of eplerenone and losartan, in a rat model of RV failure
due to chronic pressure load. We found that Ep/Lo neither prevented
adverse remodeling, nor clinical RV failure nor affected RV function.
Our ﬁndings show that RAAS inhibition does not beneﬁcially affect
experimental RV failure due to chronic pressure load, which is in strong
contrast to previous ﬁndings in the left ventricle [15,33–37]. These
data indicate that response of the pressure loaded RV to RAAS inhibition
might differ fundamentally from that of the (pressure loaded) LV, which
may have highly relevant clinical consequences.5. Eplerenone and losartan: works in the LV, not in the RV?
Pharmacotherapeutic guidelines developed for treating LV failure
serve as a roadmap in the search for effective treatments for RV failure.
Even though an increasing catalog of clinical studies of ACEi [21,22]
or ARBs [23–25] in patients with a pressure loaded RV has reported
negative results, the paradigm remains that RAAS inhibition should
work in RV dysfunction. The negative results of the studies are assumed
to be attributable to insufﬁcient power, short follow-up or retrospective
set-up of these studies [26]. Although the putative beneﬁts of RAAS
inhibition in this population certainly should not dismissed at this
point, the results of our study suggest a more fundamental explanation
for the lack of clinical effect.
A distinctive characteristic of the current study is the severity of
the PAB model which, in contrast to previously described PAB models
[38–40], induces a clear phenotype of clinical and functional RV failure.
Previous studies of ACEi and ARB in PABmodels showed no effect on RV
hypertrophy [41–44] in compensated RV pressure loading. Our study
adds the clinically relevant notion that Ep/Lo treatment does not affect
RV remodeling nor function in severe pressure load induced RV failure.
PAB rats had reduced cardiac output, activation of the systemic RAAS
(conﬁrmed by blood pressure effect of Ep/Lo), and activation of local
RAAS (conﬁrmed by downregulation of the AT1-receptor [45]). The
dosages of Ep/Lo and the administration regimens that were used in
the current study have been shown to effectively target LV disease
[15,16,28,29]. The lack of treatment effects then, suggests that the RV
responds differently to RAAS inhibition than the LV.
The contribution of the RAAS to LV remodeling and function in ﬁxed
LV pressure load is well established [46,47]. Multiple studies show that
Fig. 3. Fibrosis, hypertrophy and capillary density. A RVﬁbrosis (representative images in two top rows of pictures:Masson Trichrome stainedRVs, ruler is 1 mm, black boxwidth 1.3 mm)
B RV free wall weight normalized for tibia length (measure of RV hypertrophy) C RV cardiomyocyte cross-sectional area (third row of pictures: representative images of RV sections stained
with amembranemarker (wheat germ agglutinin, green), ruler is 125 μm). D RV capillary density, expressed as number of capillaries per 100 ∗ 100 μm(bottom row: representative images
of RV sections stained with capillary-marker lectin, ruler is 125 μm). Mean ± SEM. * indicates p b 0.05 vs. CON. CON= control, PAB= pulmonary artery banding (untreated), PAB-eplo=
PAB treated with eplerenone/losartan.
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and improve function in the aortic constriction model [15,17,33–37].
In contrast, the contribution of RAAS to RV remodeling and function
is insufﬁciently studied. RV pressure load activates local RAAS, even in
the absence of systemic RAAS activation in mild PAB [41]. However,
blocking local RAAS activation by losartan did not prevent remodeling
or improve papillary length–tension relationship [41]. The current
study shows that it also does not affect RV function in vivo. One expla-
nation might be that the local RAAS system of the RV functions differ-
ently than that of the LV. This is supported by our observation that theFig. 4. Effects of treatment on systemic pressures. A left ventricular (LV) peak pressure B ao
vs. CON; † indicates p b 0.05 vs. PAB. CON = control, PAB = pulmonary artery banding (‘beneﬁcial’ AT2-receptor, which is upregulated in the pressure loaded
LV [48], was not upregulated in the pressure loaded RV. Additionally, in
RV pressure load, the AT1-receptor has been shown to be functionally
uncoupled from its downstream effectors [42] and protein kinase C
isozymes [44], which are important regulators of remodeling and func-
tion in the LV. This could explain why RAAS inhibition, as employed in
the current study, does not work in the RV.We added an aldosterone re-
ceptor blocker, eplerenone, to the losartan treatment to circumvent the
possibility that compensatory activation of the aldosterone-pathway
(partially) negates the inhibitory effects on AT1-receptor [15,49]. Indeed,rta maximum pressure C aorta minimum pressure. Mean ± SEM. * indicates p b 0.05
untreated), PAB-eplo = PAB treated with eplerenone/losartan.
Table 1
Pressure–volume and echocardiographic parameters at termination.
CON PAB PAB-eplo p-value treatment
Pressure–volume parameters RV
Heart rate (/min) 308 ± 5 264 ± 10* 266 ± 10* 1.00
Peak pressure (mm Hg) 25 ± 1 76 ± 4* 67 ± 4* 0.25
End diastolic pressure (mm Hg) 1 ± 1 4 ± 1* 4 ± 1* 1.00
Stroke volume (μL) 426 ± 30 227 ± 23* 224 ± 18* 1.00
Cardiac index (mL/min/g BW) 0.32 ± 0.01 0.16 ± 0.02* 0.16 ± 0.02* 1.00
End systolic elastance (mm Hg/mL) 40 ± 3 175 ± 40* 118 ± 15* 0.63
Tau corrected for cycle length (ms/s) 90 ± 2 109 ± 5* 103 ± 6* 1.00
End diastolic elastance (mm Hg/mL) 1.9 ± 0.2 21.9 ± 5.0* 13.3 ± 3.0* 0.44
Arterial elastance (mm Hg/mL) 45 ± 3 255 ± 47* 222 ± 33* 1.00
Echocardiographic parameters at termination
Heart rate (/min) 368 ± 6 308 ± 8* 302 ± 8* 1.00
PAB gradient (mm Hg) N/A 78 ± 9 71 ± 5 1.00
Stroke volume (μL) 426 ± 30 227 ± 23* 224 ± 18* 1.00
TAPSE (mm) 3.4 ± 0.2 1.6 ± 0.1* 1.8 ± 0.1* 1.00
RVEDD (mm) 4.5 ± 0.1 6.5 ± 0.2* 6.7 ± 0.4* 1.00
RA diameter (mm) 4.5 ± 0.1 6.8 ± 0.3* 7.0 ± 0.4 1.00
Tricuspid insufﬁciency (fraction) 0/7 12/12* 16/17* 1.00
Pericardial effusion (fraction) 0/7 3/12 6/17 0.69
BW=bodyweight, PAB=pulmonary artery banding, TAPSE= tricuspid annular plane systolic excursion, RVEDD=RV end diastolic diameter, RA= right atrium. Data aremean ± SEM.
* indicates p b 0.05 vs. CON, p-values for eplerenone/losartan effect in right-hand column.
187M.A. Borgdorff et al. / International Journal of Cardiology 169 (2013) 183–189in the LV, pharmacological inhibition on both levels of the RAAS resulted
in more pronounced improvement of remodeling and function than
monotherapy [16].
Taken together, these data indicate important differences between
the RV and LV with regard to RAAS activation due to increased pressure
load and the response to RAAS inhibiting therapy. From the currently
available data it is not clearwhether these different responses are caused
by physiological differences between the RV and LV, of by fundamental
differences between right and left ventricular cardiomyocytes, which
embryologically derive from distinct precursor cells.
Either way, the differences in both RAAS activation and response
to therapy might explain why clinical studies of RAAS inhibition inFig. 5. Pressure–volume analysis. A–C Representative pressure–volume loops of CON, PAB an
by solid lines, end diastolic pressure–volume relations indicated by dashed lines. D Survival a
eplo: 5/17. Both PAB groups had signiﬁcantly reduced survival (p b 0.05), but there was no s
CON-eplo= CON treated with eplerenone/losartan, PAB = pulmonary artery banding (untreasystemic RVs have failed to showpositive results [22,23,25]. These stud-
ies certainly do not close the book on RAAS inhibition in RV failure. A
recent preliminary study in a murine PAB model, has suggested that
stimulation of the alternative ACE2-Ang- [1–7] pathway might be ben-
eﬁcial for RV function [50]. To take the exploration of RAAS inhibition
as a treatment strategy for RV failure a step further, the local RV RAAS
activity and its differences with local LV RAAS should be further
unraveled.
Importantly, RAAS inhibition has been reported to have beneﬁcial
effects in models of pressure loaded RV associated with pulmonary
hypertension. Studies in experimental pulmonary hypertension have
described beneﬁcial effects of losartan/telmisartan treatment on RVd PAB-eplo. End systolic pressure–volume relations during vena cava occlusion indicated
nalysis. RVF-mortality/total animals per group CON: 0/7, CON-eplo: 0/8, PAB: 5/12, PAB-
igniﬁcant difference between PAB and PAB-eplo (p = 0.39). CON = control (untreated),
ted), PAB-eplo= PAB treated with eplerenone/losartan.
Table 2
Biometric parameters and RV gene expression.
CON PAB PAB-eplo p-value treatment
General
Body weight (g) 488 ± 23 455 ± 14 440 ± 13 1.00
Organ weights
RV weight/TL (mg/mm) 6.6 ± 0.4 15.1 ± 0.6* 14.2 ± 0.5* 1.00
Fulton index (mg/mg) 0.31 ± 0.01 0.72 ± 0.02* 0.73 ± 0.2* 1.00
LV + IVS weight/TL (mg/mm) 22 ± 1 22 ± 1 19 ± 1 0.41
RA weight/TL (mg/mm) 0.9 ± 0.1 3.7 ± 0.3* 3.1 ± 0.3* 0.80
LA weight/TL (mg/mm) 0.64 ± 0.03 0.69 ± 0.05 0.61 ± 0.04 1.00
Lunglobe wet/dry (mg/mg) 5.1 ± 0.1 5.1 ± 0.1 5.5 ± 0.4 1.00
Liverlobe wet/dry (mg/mg) 3.01 ± 0.03 3.16 ± 0.05* 3.26 ± 0.07* 1.00
Gene expression
AT1R/36B4 1.0 ± 0.1 0.7 ± 0.1* 0.7 ± 0.1* 1.00
AT2R/36B4 nd nd nd
MYH7/MYH6 1.0 ± 0.1 22.5 ± 2.6* 23.8 ± 2.7* 1.00
NPPA/36B4 1.0 ± 0.4 89.0 ± 11.8* 85.3 ± 10.7* 1.00
NPPB/36B4 1.0 ± 0.2 13.3 ± 0.9* 12.1 ± 0.8* 1.00
ACTA1/36B4 1.0 ± 0.1 8.0 ± 1.1* 9.8 ± 1.4* 1.00
RCAN/36B4 1.0 ± 0.1 2.6 ± 0.3* 2.2 ± 0.2* 1.00
TGFB1/36B4 1.0 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.00
COL1A2/36B4 1.0 ± 0.1 1.5 ± 0.1 1.2 ± 0.1 0.91
COL3A1/36B4 1.0 ± 0.1 1.6 ± 0.1 1.4 ± 0.2 1.00
HMOX1/36B4 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.00
Bodyweight and organweights allmeasured at termination. Gene expression normalized for 36B4 referencemRNA, expressed as fold change vs. CON. TL= tibia length, LV= left ventricle,
IVS = interventricular septum, RA = right atrium, LA = left atrium, Fulton index = RV weight/(LV + IVS weight), AT1R= angiotensin II type 1 receptor, AT2R= angiotensin II type 2
receptor, MYH7/6= β/α-myosin heavy chain, NPPA/B= natriuretic pro-peptides type A/B, ACTA=α-skeletal actin, RCAN1= regulator of calcineurin 1, TGFβ-1= transforming growth
factor-β-1, COL1A2/3A1 = collagen subunits 1A2 and 3A1, HMOX1 = hemoxygenase-1. Data are mean ± SEM. * indicates p b 0.05 vs. CON, p-values for eplerenone/losartan effect in
right-hand column.
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increased local RAAS activity has been demonstrated in pulmonary ar-
teries of patients with pulmonary arterial hypertension [52]. Therefore,
the described beneﬁcial effects of RAAS inhibition in these models are
not necessarily direct myocardial effects in the pressure loaded RV,
but may also be secondary to AT1R-inhibiting effects on the pulmonary
vasculature, leading to decreased RV-afterload and thereby secondary
to improved RVperformance and remodeling. Effects of RAAS inhibition
on the pulmonary vasculature have been reported: losartan prevented
pulmonary vascular remodeling and decreased BMPR-2 expression in
amodel of shunt-induced pulmonary hypertension [52,53]. The current
PAB model, with a ﬁxed afterload, excludes such ‘confounding’ pulmo-
nary vascular effects and thus allows assessing direct effects of RAAS
inhibition on the RV-myocardium [54]. The lack of losartan effect in
our study therefore indicates that RV effects of losartan in (experi-
mental) PH are secondary to the pulmonary vascular effects. These
experimental data suggest that RAAS inhibition may be beneﬁcial in
patients with RV failure associated with pulmonary vascular disease,
but not in patients with RV failure in the setting of CHD, in which RV-
afterload is not determined by pulmonary vascular resistance, including
systemic RV, pulmonary branch stenosis or other RV outﬂow tract
obstructions.
6. Limitations
The current experiments were designed to test the preventive effects
of a ‘clinical’ Ep/Lo treatment strategy on RV remodeling and function.
In the clinical setting, therapeutic effects that reverse established
remodeling/dysfunction are of high importance. However, given the
lack of preventive beneﬁts, it is unlikely Ep/Lo would have therapeutic
effects in the pressure loaded RV. Secondly, we did not include mono-
therapy groups treated with losartan or eplerenone. Although, in light
of the lack of effects of the combination treatment, it seems unlikely
that monotherapy would have beneﬁcial effects in PAB, we cannot con-
clude this ﬁrmly based on the present study. As in all preclinical studies,
caution is required when data from experimental models are extra-
polated to the clinical setting.7. Conclusion
Combination treatment with eplerenone and losartan did not
prevent adverse remodeling, clinical RV failure or beneﬁt RV function
in a model of pressure load induced RV failure.
Our ﬁndings indicate that local RAAS activation in the pressure
loaded RV and its response to effective RAAS inhibition differ from
that in the LV. This is of high clinical relevance when treating patients
with RV dysfunction due to abnormal loading conditions. To further ex-
plore a potential role for RAAS inhibition in the treatment of RV failure,
the local RV RAAS activity and its differences with local LV RAAS should
be unraveled.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2013.08.102.
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